Resumen de Impacto presupuestario de los tratamientos antirretrovirales
José Antonio Martín Conde, P. Viejo Rivero, E. Sánchez Garmendia, Gádor A. Callejón Callejón, Sara Ramos Linares
In our hospital the cost of antiretroviral drugs is 20-24% of the pharmacy expenditure and each year increases mainly for new drugs introduction. Objective: To describe drug combinations used in our hospital and cost related without to consider health effects from those treatments. Method: We calculate the cost of each therapeutic combination. We retrospectively analyzed antiretroviral drugs prescribed to adults with HIV infection during one year, describing: a) combinations used, b) treatment changes and c) number of patients naïve and their therapeutic profile. Results: From 602 patients attended by Pharmacy Department at least once to pick up medicines prescribed, 118 different combinations were identified. 129 therapeutic profile modifications were detected and 141,835.49 euros was their cost associated. 85 naïve patients were identified. 25 different antiretroviral drug combinations were identified with an associate cost of 316,167.03 euros. Conclusions: In this analysis Trizivir® was the combination most used and 3TC/TDF/EFV was the combination with greater impact. A series of actions are perceptive on several levels of clinical management with efficiency and fairness goal
